This is a Phase II study designed to estimate the efficacy of weekly low-dose PEG-Intron in pediatric patients with CNS tumors, beginning 2-10 weeks after completion of radiation therapy. The endpoint of the trial is 2-year survival compared to historical controls who have received radiation alone. Patients undergo extensive imaging analysis. Accrual to this trial has been completed, patients are being followed for endpoint analyses, and biologic samples are being evaluated. All patients have tolerated the PEG-Intron therapy well, with no adverse events directly attributable to the study agent. Overall study results, including 2 year survival, have been published in the journal, Cancer. We showed that patients receiving PEG-Intron have a median time to progression of 7 months compared to similar patients on recently completed consortia trials, who have a median time to progression of 4-5 months. Accrual to this trial and the primary endpoint are complete. We are now evaluating batched patient samples for a number of biomarkers, which will be correlated to outcome.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Warren, Katherine E (2012) Diffuse intrinsic pontine glioma: poised for progress. Front Oncol 2:205
Warren, Katherine; Bent, Robyn; Wolters, Pamela L et al. (2012) A phase 2 study of pegylated interferon ?-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma. Cancer 118:3607-13
Ko, Christine; Kaushal, Aradhana; Hammoud, Dima A et al. (2012) Role of early postradiation magnetic resonance imaging scans in children with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 83:1252-6
Steffen-Smith, Emilie A; Venzon, David J; Bent, Robyn S et al. (2012) Single- and multivoxel proton spectroscopy in pediatric patients with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 84:774-9